Axoltis Pharma
PrivateLast Round
Series A
Dec 2, 2025
Est. Valuation
$37.63M
Total Funding Raised
$23.32M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Axoltis Pharma operates in Healthcare & Life Sciences and is based in Clermont-Ferrand. Its latest recorded funding round was a Series A round in December 2025.
Axoltis Pharma is a biotechnology company that develops innovative drugs for neurodegenerative and neurotraumatic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Axoltis Pharma Comparables
Compare Axoltis Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AL-S Pharma AG | 81% | |
| Primary Peptides, Inc. | 80% | |
| Revalesio | 79% |
For institutional investors. Book with your work email.
Axoltis Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 2, 2025 | ||||
| Seed | Jun 15, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Axoltis Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ODDO BHF Group | Series A |
| UI Investissement | Seed, Series A |
| Angelor | Seed, Series A |
| Norfoalk | Series A |
| Sofimac Investment Managers | Seed, Series A |
| Capital Cell | Series A |
| Cenitz | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 1, 2026
Open roles increased to 7, 47% of headcount.
- Jul 24, 2026
Monthly visitors increased 6587% MoM, from 30 to 2K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 16, 2026
Axoltis is developing NX210c for neurodegenerative and trauma-related disorders based on proposed blood-brain barrier restoration, neuroprotection and improved neurotransmission.
For institutional investors. Book with your work email.
Axoltis Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Axoltis Pharma's valuation, stock price, and market status.
Is Axoltis Pharma a public or private company?
Axoltis Pharma is a private company.
What is the current stock price of Axoltis Pharma?
Axoltis Pharma is a private company, so its shares have no public market price. Caplight tracks Axoltis Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Axoltis Pharma worth (valuation)?
Axoltis Pharma's valuation is estimated at $37.6M based on funding round data.
Can I buy Axoltis Pharma stock?
Axoltis Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Axoltis Pharma's last funding round?
Axoltis Pharma's most recent funding round was Series A on December 2, 2025.
Who are the main investors in Axoltis Pharma?
Key investors in Axoltis Pharma include ODDO BHF Group, Cenitz.
Will Axoltis Pharma IPO soon?
No public IPO plans have been announced for Axoltis Pharma.
How can I track Axoltis Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Axoltis Pharma's shares on secondary markets.